IP Library Patent Application 13606696
Patent Application
App. No. 13/606,696

ACTIVATION INDUCED DEAMINASE (AID)

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/606,696
Abstract

The invention is directed to a cell comprising a nucleic acid encoding an Activation Induced Deaminase (AID) polypeptide, a fusion protein comprising an AID polypeptide, and methods of using a nucleic acid encoding an AID polypeptide.

Claims (29)

1 . A cell comprising a nucleic acid encoding an Activation Induced Deaminase (AID) polypeptide, or an AID variant, derivative or homologue, and having a mutator phenotype.

2 . The cell of claim 1 , wherein said cell is a prokaryotic cell.

3 . The cell of claim 1 , wherein said cell is an eukaryotic cell.

4 . The cell of claim 1 , wherein the AID homologue is Apo1bec-1, Apobec-1, Apobec3C or Apobec3G.

5 . A fusion protein comprising an AID polypeptide, or AID variant, derivative or homologue thereof, having a mutator phenotype operably linked to one half of a specific binding pair.

6 . The fusion protein of claim 5 , wherein said one half of a specific binding pair is a DNA binding domain.

7 . A vector comprising a nucleic acid encoding the fusion protein of claim 5 .

8 . A cell comprising a nucleic acid encoding the fusion protein of claim 5 .

9 . A method for preparing a gene product having a desired activity, comprising the steps of:

a) expressing a nucleic acid encoding the gene product in a population of cells according to claim 1 ;

b) identifying a cell or cells within the population of cells which expresses a mutant gene product having the desired activity; and

c) establishing one or more clonal populations of cells from the cell or cells identified in step (b), and selecting from said clonal populations a cell or cells which expresses a gene product having an improved desired activity.

10 . A method as claimed in claim 9 , wherein the nucleic acid encoding the gene product is operably linked to the second half of a specific binding pair.

11 . A method of directing mutation to a specific gene product of interest comprising:

i) generating a nucleic acid construct comprising a nucleic acid sequence encoding a specific gene product operably linked to a DNA binding protein recognition sequence;

ii) transfecting said nucleic acid construct into a population of host cells expressing the fusion protein of claim 6 ;

ii) incubating said transfected host cells under conditions suitable for allowing the specific binding pairing of DNA binding protein to DNA binding protein recognition sequence to occur;

iv) identifying a cell or cells within the population of cells which expresses a mutant gene product having the desired activity; and

v) establishing one or more clonal populations of cells from the cell or cells

identified in (iv), and selecting from said clonal populations a cell or cells which expresses a gene product having an improved desired activity.

12 . A method of identifying components of AID-dependent mutation activity comprising expressing AID in a cell deficient in expression or activity of a known gene and assessing mutator activity compared to activity in a cell expressing said gene.

13 . A method of screening for a modulator of AID activity comprising:

(a) expressing AID in a prokaryotic cell;

(b) maintaining the AID-expressing prokaryotic cell in the presence of a selectable medium;

(c) detecting the presence of colonies in the absence or presence of a test compound, wherein a modified number of colonies when compared to a sample in the absence of a test compound is indicative of the ability of the test compound to modify AID mutator activity.

14 . A method of inducing a mutation in a cell comprising administering an AID polypeptide or functional homologue thereof.

15 . A method for treating a disorder characterized by an increased mutation rate, comprising administering an agent that modifies AID functional activity or gene expression.

16 . A method of decreasing hypermutation/resistance to a compound such as an antibiotic in a population of bacteria comprising modulating activity of a bacterial AID homologue.

17 . A construct for use in the method of claim 11 , said construct comprising a coding sequence for the gene product of interest, wherein said coding sequence is placed under the control of a first promoter upstream of the coding sequence and further comprising a second promoter downstream of the coding sequence, wherein said first and second promoters are arranged in opposing orientation so as to allow convergent transcription of the coding sequence.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 2, 2018
From: MEDICAL RESEARCH COUNCIL
To: UNITED KINGDOM RESEARCH AND INNOVATION
Reel/Frame 046469/0108 →